Salarius Pharmaceuticals Announces 1-for-15 Reverse Stock Split
HOUSTON, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX), a clinical-stage biopharmaceutical company using protein inhibition and...
HOUSTON, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX), a clinical-stage biopharmaceutical company using protein inhibition and...
GLEN ALLEN, Va., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage...
BOSTON, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company...
Kennewick, WA, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL) Following the 30-day review period, the FDA declined...
Landmark AI-driven analysis backed by The Gates Foundation sets stage for transformative treatments in one of the world's most underserved...
Webinar to Review Results from Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study Evaluating Allocetra™ in Patients with Moderate to Severe Knee Osteoarthritis...
10-minute home test enables detection of Helicobacter pylori, a leading cause of peptic ulcers, dyspepsia, and gastric cancerH. pylori linked...
REDWOOD CITY, CA, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Biotricity Inc. (OTCQB:BTCY) ("Biotricity" or the "Company”), an innovative Technology-as-a-Service (TaaS)...
Ra’anana, Israel, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (“Polyrizon” or the “Company”), a biotechnology company focusing...
Veteran commercial leader to scale AI-enabled NAMkind™ liver and intestine toxicology services in a rapidly growing marketSAN DIEGO, Aug. 14,...
Breakthrough Epigenetic Modulator LB-100 Targets Ovarian Clear Cell Carcinoma, Advanced Soft Tissue Sarcoma, and MSS Metastatic Colon CancerDENVER, Aug. 14,...
Presented positive results from the phase 3 randomized, placebo-controlled clinical trial of CAN-2409 (aglatimagene besadenovec) in localized prostate cancer, during...
First commercial sales of LYTENAVA™ (bevacizumab gamma) achieved in EuropeONS-5010/LYTENAVA™ (bevacizumab-vikg) Prescription Drug User Fee Act (PDUFA) goal date of...
NEW HAVEN, Conn., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Halda Therapeutics, a clinical-stage biotechnology company developing a novel class of...
WESTBROOK, Maine, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Synergy CHC Corp. (NASDAQ: SNYR) (“Synergy” or the “Company”), a consumer health...
Favorable CDI-988 Phase 1 safety and tolerability reported Challenge study with CDI-988 as a norovirus preventive and treatment planned later this...
TORONTO, Aug. 14, 2025 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a specialty...
Echocardiographic data analysis demonstrated favorable impact of atrioventricular interval modulation (“AVIM”) therapy on MODERATO II study patients with diastolic dysfunction,...
Study achieves primary sensitivity endpoint, advancing diagnostics for heart failure with preserved ejection fraction (HFpEF) and pulmonary hypertension (PH)Results build...
Ickey & Jovante Woods Ickey Woods with his son Jovante. Company and Former Cincinnati Bengals Running Back Known for the...